医学
荟萃分析
置信区间
掌跖脓疱病
随机对照试验
优势比
梅德林
分级(工程)
系统回顾
随机效应模型
内科学
物理疗法
皮肤病科
银屑病
土木工程
政治学
法学
工程类
作者
Takemichi Fukasawa,Takashi Yamashita,Atsushi Enomoto,Asako Yoshizaki‐Ogawa,Kiyoshi Miyagawa,Shinichi Sato,Ayumi Yoshizaki
摘要
Abstract Few studies have made direct comparisons between treatments for palmoplantar pustulosis (PPP); therefore, it is difficult to select the best treatment for each patient. To determine the best therapy and to compare reported measures of efficacy in clinical trials of systemic treatments for PPP in this systematic review and network meta‐analysis. Six databases were used to perform database search on 10 July 2022. Randomized controlled trials (RCTs) were identified through a systematic literature search. The titles and abstracts of articles were initially screened for inclusion by two authors independently using our predetermined criteria. The full texts of selected articles were then independently assessed for inclusion in a blinded fashion. Disagreement between the authors was resolved by consensus. Data were abstracted in duplicate. Random‐effects model was accepted to perform network meta‐analysis. Assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed according to the PRISMA guidelines. The analysis was completed in July 2022. The primary outcome was the change of PPP Area and Severity Index (PPPASI) from baseline and the secondary outcome was the achievement of PPPASI‐50 response. Seven RCTs with 567 patients were included. Guselkumab 100 mg was the one with the highest probability of reaching the proposed outcomes (mean difference [MD], −8.00; 95% confidence interval [CI], 4.88–11.11), while the achievement of PPPASI‐50 response did not show a significant difference (odds ratio [OR], 3.79; 95% CI, 0.51–28.37). Guselkumab 200 mg was next to 100 mg of reaching the proposed outcomes (MD, −4.71; 95% CI, 2.12–7.30), while the achievement of PPPASI‐50 response did not show a significant difference (OR, 2.34; 95% CI, 0.48–11.43). Network meta‐analysis showed guselkumab 100 mg was the treatment with the highest probability of reaching both PPPASI and PPPASI‐50 outcomes. Absolute PPPASI may be more appropriate as an outcome than PPPASI‐50.
科研通智能强力驱动
Strongly Powered by AbleSci AI